JERUSALEM, June 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that it has been selected to display its abstract, entitled Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin in Healthy Subjects, at the upcoming 68th Annual American Diabetes Association's Scientific Sessions Conference in San Francisco, highlighting the successful results from its oral insulin trials on healthy volunteers.
The abstract will also be printed in the Scientific Sessions Abstract Book, the June 2008 supplement to the journal Diabetes.
Oramed's technology will be included in an oral presentation by Prof. Dr. Lutz Heinemann, CEO of Profil Institute for Metabolic Research, "Pharmacokinetics and Pharmacodynamics of Alternate Insulin Delivery Systems," on Saturday, June 7, 2008 from 4 pm to 6 pm.
"The selection of Oramed as one of the companies to exhibit at Scientific Sessions is a great opportunity that allows us to present our data from human trials to the leading scientists in the diabetes field from all over the world," said Nadav Kidron, Oramed CEO.
Oramed's abstract poster has been assigned presentation number 425-P Clinical Therapeutics/New Technology - Insulin Delivery Systems and is available for viewing throughout the conference. A representative of the company will be available to answer questions on Saturday, June 7 from 6-7PM and from 12-2PM on Monday, June 9 at San Francisco's Moscone Convention Center, Hall D.
For more information about the ADA and the upcoming conference, please visit http://professional.diabetes.org.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
For more information, please visit http://www.oramed.com
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the
risks and uncertainties related to the progress, timing, cost, and results
of clinical trials and product development programs; difficulties or delays
in obtaining regulatory approval for our product candidates; competition
from other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its research,
development and commercialization activities. Please refer to the company's
filings with the Securities and Exchange Commission for a comprehensive
list of risk factors that could cause actual results, performance or
achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no
obligation to update or revise any forward-looking statements.
Company and Investor Relation Contacts:
Email: email@example.com .
Ruder Finn Israel for Oramed,
Email: firstname.lastname@example.org .
|SOURCE Oramed Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved